Search results for " deficiency"

showing 10 items of 669 documents

Nitric oxide and glutathione impact the expression of iron uptake- and iron transport-related genes as well as the content of metals in A. thaliana p…

2012

International audience; Mounting evidence indicate that nitric oxide (NO) acts as a signaling molecule mediating iron deficiency responses through the upregulation of the expression of iron uptake-related genes. Accordingly, NO donors such as nitrosoglutathione (GSNO) were reported to improve the fitness of plants grown under iron deficiency. Here, we showed that glutathione, a by-product of GSNO, triggered the upregulation of the expression of iron uptake- and transport-related gene and an increase of iron concentration in Arabidopsis thaliana seedlings facing iron deficiency. Furthermore, we provided evidence that under iron deficiency, NO released by GSNO did not improve the root iron co…

0106 biological sciencesmineral contentShort CommunicationIron[SDV]Life Sciences [q-bio]ArabidopsisPlant ScienceGenes PlantNitric Oxide01 natural sciencesPlant RootsNitric oxideS-Nitrosoglutathione03 medical and health scienceschemistry.chemical_compoundDownregulation and upregulationGene Expression Regulation PlantArabidopsismineral deficienciesmedicineArabidopsis thalianaglutathione030304 developmental biologymineral uptakeRegulation of gene expression0303 health sciencesManganesebiologyArabidopsis Proteinsarabidopsis thalianaBiological TransportIron deficiencyGlutathioneIron Deficienciesbiology.organism_classificationmedicine.diseaseZincchemistryBiochemistryS-Nitrosoglutathione[SDE]Environmental Sciencesgene expressionCopper010606 plant biology & botany
researchProduct

Ferroterapia en el manejo de la anemia en la enfermedad renal crónica no en diálisis: perspectiva del grupo de anemia de la S.E.N

2021

Resumen: Este trabajo realiza una actualización sobre el manejo del déficit de hierro en pacientes con enfermedad renal crónica (ERC), ya sea con o sin anemia. Se revisan las recomendaciones de las guías para el tratamiento de la ferropenia en la ERC. Además, muestra los nuevos estudios sobre ferroterapia en pacientes con ERC, así como los nuevos conocimientos sobre el déficit férrico y su impacto en los resultados clínicos.La anemia es una complicación frecuente de la ERC y se asocia con una disminución en la calidad de vida de los pacientes, así como un aumento de la morbimortalidad. El déficit de hierro (absoluto o funcional) es frecuente en pacientes con ERC que no reciben diálisis y pu…

03 medical and health sciences0302 clinical medicineNephrologyIronIron deficiencyIron deficitChronic kidney disease030232 urology & nephrologyAnaemiaHaemoglobin030204 cardiovascular system & hematologylcsh:Diseases of the genitourinary system. Urologylcsh:RC870-923Nefrología
researchProduct

Iron deficiency and risk of early readmission following a hospitalization for acute heart failure

2016

03 medical and health sciencesmedicine.medical_specialty0302 clinical medicinebusiness.industryHeart failureInternal medicinemedicine030212 general & internal medicineIron deficiency030204 cardiovascular system & hematologyCardiology and Cardiovascular Medicinemedicine.diseasebusinessEuropean Journal of Heart Failure
researchProduct

Management of patients with hereditary angioedema in Germany: comparison with other countries in the Icatibant Outcome Survey

2018

Abstract Background The Icatibant Outcome Survey (IOS; NCT01034969) is a Shire‐sponsored, international, observational study monitoring the safety and effectiveness of icatibant, a bradykinin B2 receptor antagonist approved for the acute treatment of adults with hereditary angioedema with C1 inhibitor deficiency (HAE‐C1‐INH). Objective To report IOS data comparing demographic and icatibant treatment outcomes in patients with HAE‐C1‐INH from Germany to HAE‐C1‐INH patients from 11 other IOS countries. Methods A descriptive, retrospective, comparative analysis of data from 685 IOS patients with HAE‐C1‐INH from seven centres in Germany (n = 93) vs. centres from Austria, Brazil, Czech Republic, …

0301 basic medicineAdultMalePediatricsmedicine.medical_specialtyTime FactorsC1 inhibitor deficiencyTime to treatmentDermatologyBradykininAutoimmune DiseasesTime-to-Treatment03 medical and health scienceschemistry.chemical_compound0302 clinical medicineIcatibantGermanyBradykinin B2 Receptor AntagonistsmedicineHumansIn patientSymptom onsetRetrospective Studiesbusiness.industryAngioedemas HereditaryMiddle Agedmedicine.diseaseSymptom Flare UpHealth Surveys030104 developmental biologyInfectious Diseases030228 respiratory systemchemistryHereditary angioedemaObservational studyOriginal ArticleFemaleOutcome databusinessJournal of the European Academy of Dermatology and Venereology
researchProduct

Altered chemotactic response to CXCL12 in patients carrying GATA2 mutations.

2015

Abstract GATA2 deficiency—formerly described as MonoMAC syndrome; dendritic cells, monocytes, B cells, and natural killer cell deficiency; familial myelodysplastic syndrome/acute myeloid leukemia; or Emberger syndrome—encompasses a range of hematologic and nonhematologic anomalies, mainly characterized by monocytopenia, B lymphopenia, natural killer cell cytopenia, neutropenia, immunodeficiency, and a high risk of developing acute myeloid leukemia. Herein, we present 7 patients with GATA2 deficiency recruited into the French Severe Chronic Neutropenia Registry, which enrolls patients with all kinds of congenital neutropenia. We performed extended immunophenotyping of their whole blood lymph…

0301 basic medicineAdultMaleReceptors CXCR4AdolescentLymphocyteT-LymphocytesImmunologyMonocytopeniaBiologyNatural killer cell03 medical and health sciencesYoung AdultImmunophenotypinghemic and lymphatic diseasesmedicineImmunology and AllergyHumansLymphocyte CountCongenital NeutropeniaChildAgedCytopeniaB-LymphocytesGATA2 DeficiencyTraditional medicineChemotaxisCell MembraneMyeloid leukemiaCell Biologymedicine.diseaseCD56 AntigenChemokine CXCL12GATA2 Transcription FactorKiller Cells Natural030104 developmental biologymedicine.anatomical_structureImmunologyMutationFemaleJournal of leukocyte biology
researchProduct

Roux-en-Y Gastric Bypass as an Effective Bariatric Revisional Surgery after Restrictive Procedures

2020

<b><i>Introduction:</i></b> Revisional surgery must be considered when insufficient weight loss is attained or weight is subsequently regained. This study aimed to investigate the value of Roux-en-Y gastric bypass (RYGB) as a revisional procedure after restrictive surgery. <b><i>Materials and Methods:</i></b> An observational, retrospective study including patients initially operated on for morbid obesity with restrictive techniques (vertical-banded gastroplasty [VBG], adjustable gastric band [AGB], and sleeve gastrectomy) and reoperated with RYGB in our centre between December 1994 and January 2019. Demographic and anthropometric data, associ…

0301 basic medicineAdultReoperationSleeve gastrectomymedicine.medical_specialtyHealth (social science)Gastroplastymedicine.medical_treatmentGastric bypassGastric BypassPulmonary diseaseBariatric Surgerylcsh:TX341-641030209 endocrinology & metabolismComorbidity03 medical and health sciences0302 clinical medicineWeight lossPhysiology (medical)Weight LossmedicineHumansAdjustable gastric bandIntraoperative Complicationslcsh:RC620-627Retrospective Studies030109 nutrition & dieteticsbusiness.industryMortality rateRetrospective cohort studyLength of StayMiddle AgedRoux-en-Y anastomosisSurgeryObesity Morbidlcsh:Nutritional diseases. Deficiency diseasesconversion surgeryinsufficient weight lossmedicine.symptombusinesslcsh:Nutrition. Foods and food supplyResearch Article
researchProduct

Overexpression of glucose 6 phosphate dehydrogenase preserves mouse pancreatic beta cells function until late in life.

2021

NAD(P)H donates electrons for reductive biosynthesis and antioxidant defense across all forms of life. Glucose-6- phosphate dehydrogenase (G6PD) is a critical enzyme to provide NADPH. G6PD deficiency is present in more than 400 million people worldwide. This enzymopathy provides protection against malaria but sensitizes cells to oxidative stressors. Oxidative stress has been involved in the pathogenesis of the diabetic complications and several studies have provided evidences of a link between G6PD deficiency and type 2 diabetes (T2D). We hypothesized that a moderate overexpression of G6PD (G6PD-Tg) could protect β-cells from age-associated oxidative stress thus reducing the risk of develop…

0301 basic medicineAgingmedicine.medical_specialtyOxidative phosphorylationType 2 diabetesGlucosephosphate Dehydrogenasemedicine.disease_causeBiochemistry03 medical and health scienceschemistry.chemical_compoundMice0302 clinical medicinehemic and lymphatic diseasesPhysiology (medical)Internal medicineDiabetes mellitusInsulin-Secreting Cellsparasitic diseasesNADPHmedicineGlucose-6-phosphate dehydrogenaseAnimalsPancreatic isletsDiabetesWild typenutritional and metabolic diseasesmedicine.diseaseOxidative Stress030104 developmental biologyEndocrinologymedicine.anatomical_structureGlucosephosphate Dehydrogenase DeficiencychemistryDiabetes Mellitus Type 2Oxidative stressPancreas030217 neurology & neurosurgeryOxidative stressFree radical biologymedicine
researchProduct

The Antioxidant Therapy: New Insights in the Treatment of Hypertension

2018

Reactive oxygen species (ROS) and reactive nitrogen species (RNS) play a key role in the regulation of the physiological and pathological signaling within the vasculature. In physiological conditions, a delicate balance between oxidants and antioxidants protects cells from the detrimental effects of ROS/RNS. Indeed, the imbalance between ROS/RNS production and antioxidant defense mechanisms leads to oxidative and nitrosative stress within the cell. These processes promote the vascular damage observed in chronic conditions, such as hypertension. The strong implication of ROS/RNS in the etiology of hypertension suggest that antioxidants could be effective in the treatment of this pathology. I…

0301 basic medicineAntioxidantPhysiologymedicine.medical_treatmentReview030204 cardiovascular system & hematologymedicine.disease_causeEssential hypertensionBioinformaticslcsh:Physiologyvitamin D deficiencyNitrosative stre03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePhysiology (medical)medicineVitamin D and neurologyoxidative stressReactive nitrogen specieslcsh:QP1-981business.industryROSmedicine.diseasenitrosative stressNebivololantioxidants030104 developmental biologyBlood pressurechemistryHypertensionOxidative streAntioxidantbusinessOxidative stressmedicine.drugFrontiers in Physiology
researchProduct

Safe neoadjuvant trastuzumab-based treatment in HER2 + inflammatory early breast cancer in a glucose 6-phosphate dehydrogenase-deficient postmenopaus…

2019

Introduction Glucose 6-phosphate dehydrogenase (G6PD) is a basic antioxidant pathway for erythrocytes, being its deficiency the most common gene mutation worldwide. As breast cancer is one of the most frequent tumors, many of these patients may present with G6PD deficiency prior treatment without notice. Case report We present the case of a woman deficient for G6PD with the diagnosis of Stage IIIB (cT4d cN1 cM0) HER2-enriched early breast cancer. Management and outcome The patient underwent neoadjuvance with trastuzumab and anthracycline-free chemotherapy, based on docetaxel (75 mg/m2, 120 mg) and carboplatin (AUC 5, 560 mg). She did not present hemolytic crisis and no blood transfusions we…

0301 basic medicineAntioxidantReceptor ErbB-2medicine.medical_treatmentCommon geneBreast NeoplasmsDehydrogenasemedicine.disease_cause03 medical and health scienceschemistry.chemical_compoundAntineoplastic Agents Immunological0302 clinical medicineBreast cancerTrastuzumabmedicineHumansGlucose-6-phosphate dehydrogenasePharmacology (medical)skin and connective tissue diseasesAgedEarly breast cancerMutationbusiness.industryTrastuzumabmedicine.diseaseNeoadjuvant TherapyPostmenopauseGlucosephosphate Dehydrogenase DeficiencyTreatment Outcome030104 developmental biologyOncologychemistry030220 oncology & carcinogenesisCancer researchFemalebusinessmedicine.drugJournal of Oncology Pharmacy Practice
researchProduct

Yeast Cth2 protein represses the translation of ARE-containing mRNAs in response to iron deficiency

2018

In response to iron deficiency, the budding yeast Saccharomyces cerevisiae undergoes a metabolic remodeling in order to optimize iron utilization. The tandem zinc finger (TZF)-containing protein Cth2 plays a critical role in this adaptation by binding and promoting the degradation of multiple mRNAs that contain AU-rich elements (AREs). Here, we demonstrate that Cth2 also functions as a translational repressor of its target mRNAs. By complementary approaches, we demonstrate that Cth2 protein inhibits the translation of SDH4, which encodes a subunit of succinate dehydrogenase, and CTH2 mRNAs in response to iron depletion. Both the AREs within SDH4 and CTH2 transcripts, and the Cth2 TZF are es…

0301 basic medicineCancer ResearchRNA StabilityAdaptation BiologicalGene ExpressionBiochemistryGene Expression Regulation FungalGene expressionMedicine and Health SciencesExpressió genèticaGenetics (clinical)Regulation of gene expressionZinc fingerbiologyMessenger RNANutritional DeficienciesEukaryotaTranslation (biology)Iron DeficienciesCell biologyNucleic acidsDNA-Binding ProteinsCellular Structures and OrganellesResearch ArticleSaccharomyces cerevisiae Proteinslcsh:QH426-470IronProtein subunitSaccharomyces cerevisiaeSaccharomyces cerevisiaeDNA constructionRegulatory Sequences Ribonucleic Acid03 medical and health sciencesExtraction techniquesTristetraprolinPolysomeGeneticsRNA MessengerMolecular BiologyEcology Evolution Behavior and SystematicsNutritionAU Rich ElementsAU-rich elementBiology and life sciencesOrganismsFungiCell Biologybiology.organism_classificationYeastRNA extractionResearch and analysis methodslcsh:GeneticsMolecular biology techniques030104 developmental biologyPolyribosomesPlasmid ConstructionIron DeficiencyRNAProtein TranslationRibosomesTranscription Factors
researchProduct